The significant efficiency of PARP1 inhibition on the survival of HR defective tumors has led to the development of several PARP inhibitors that are currently in clinical trials, and clinical benefits have been achieved in BRCA-mutated ovarian, breast, and prostate cancers. The gene discussed is PARP1; the disease is Familial prostate cancer.